Skip to main content
Figure 1. | BMC Infectious Diseases

Figure 1.

From: Immunogenicity and safety of a recombinant COVID-19 vaccine (ZF2001) as heterologous booster after priming with inactivated vaccine in healthy children and adolescents aged 3-17 years: an open-labeled, single-arm clinical trial

Figure 1.

Trial profile. Eligible participants who had previously received two doses of commercially available COVID-19 inactivated vaccine in the past 5-8 months were enrolled to receive one dose of recombinant COVID-19 vaccine (ZF2001). A total of 240 participants received one dose of ZF2001. All participants were included in the full analysis set (FAS) and the safety set (SS). One participant was excluded from the per-protocol set (PPS) because of a protocol violation due to the use of an allergic medication

Back to article page

BMC Infectious Diseases

ISSN: 1471-2334

Contact us